Home > Insider Trading > Filing (0001209191-21-010401)

Filing Details

Accession Number:: 0001209191-21-010401
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-12 18:36:55
Reporting Period:: 2021-02-10

Accepted Time:: 2021-02-12 18:36:55
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1377121	Protagonist Therapeutics Inc	PTGX	Pharmaceutical Preparations (2834)	980505495

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1706301	B. Sarah Noonberg	C/O Protagonist Therapeutics, Inc. 7707 Gateway Boulevard, Suite 140 Newark CA 94560-1160		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-02-10	4,700	$6.98	4,700	No	4	A	Direct
Common Stock	Disposition	2021-02-10	4,300	$25.42	400	No	4	S	Direct
Common Stock	Disposition	2021-02-10	400	$26.04	0	No	4	S	Direct
Common Stock	Acquisiton	2021-02-11	3,700	$6.98	3,700	No	4	A	Direct
Common Stock	Disposition	2021-02-11	3,700	$25.09	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2021-02-10	4,700	$0.00	4,700	$6.98
Common Stock	Stock Option (right to buy)	Disposition	2021-02-11	3,700	$0.00	3,700	$6.98

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
7,300		2028-05-28	No	4	M	Direct
3,600		2028-05-28	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 1, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.01 to $25.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $26.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
This option is fully vested. It vested in accordance with the following schedule: the shares subject to this option shall vest at the earlier on (i) May 29, 2019, or (ii) the date of the 2019 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan).